Abstract 164P
Background
Sarcopenia is the loss of skeletal muscle mass and function that occurs with advancing age and certain diseases. It is a complication and independent risk factor for chemotherapy toxicity and mortality in patients with liver cirrhosis and hepatocellular carcinoma. The aim of this study was to study the impact of sarcopenia on chemotherapy toxicity and survival among hepatocellular carcinoma patients who underwent chemotherapy.
Methods
A systematic review was performed according to PRISMA guidelines. A literature search was conducted by two independent reviewers on all studies that included sarcopenia in hepatocellular carcinoma patients who underwent chemotherapy using PubMed, PubMed central, and Google Scholar databases. Study included elderly population was excluded. Outcome of interest included chemotherapy toxicity and overall survival. Data synthesis and statistical analysis were carried out using Review Manager software.
Results
A total of 10 studies were eligible for meta-analysis including a total of 1203 hepatocellular carcinoma patients. All included studies were retrospective cohort. Meta-analysis revealed a significant association between sarcopenia and overall survival (HR 1.76; 95% CI 1.37 – 2.25; P < 0.001). Sarcopenia was also associated with incidence of chemotherapy toxicity (OR 2.84; 95% CI 1.35 – 5.96; P = 0.006), including hand-foot syndrome, diarrhea, hepatic encephalopathy and hypertension. The quality of study assessed with Newcastle Ottawa Scale (NOS) showed “poor” in only 2 included studies while the remaining 8 studies were graded as “good”.
Conclusions
Sarcopenia can give negative impact on chemotherapy toxicities and survival outcomes for hepatocellular carcinoma patients who underwent chemotherapy. Prospective studies with a uniform definition of sarcopenia and same chemotherapy regimen are still needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Diagnostic value of micro RNA (miRNA) in renal cell cancer: A meta-analysis and systemic review
Presenter: Jestoni Aranilla
Session: e-Poster Display Session
314P - Comprehensive microbial signatures and genomic profiling in tumour samples using next generation sequencing
Presenter: Mei Qi Yee
Session: e-Poster Display Session
315P - High-penetrance breast and/or ovarian cancer susceptibility genes in Filipinos
Presenter: Frances Victoria Que
Session: e-Poster Display Session
316P - Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
Presenter: Yingnan Yu
Session: e-Poster Display Session
317P - Genomic profiling and molecular pathology of Chinese glioma patients
Presenter: yuanli Zhao
Session: e-Poster Display Session
320P - Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies
Presenter: Kelvin Bao
Session: e-Poster Display Session
321P - Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients
Presenter: Krishnamani Kalpathi
Session: e-Poster Display Session
322P - Challenged faced by cancer patients during the COVID-19 pandemic
Presenter: mithra Krishnamani
Session: e-Poster Display Session
323P - Oncology care in the Republic of Kazakhstan during COVID-19
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
324P - COVID era: Perception of oncologists from a developing nation
Presenter: Rakesh Roy
Session: e-Poster Display Session